Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.59 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.59 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.59 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.59 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.59 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 11/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.41 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918349 | 1.00 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL678338 | 1.00 | GRIN2D (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3878156 | 0.87 | PKM (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2761236 | 0.85 | PKM (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| 3-Hydroxyrimantadine SCHEMBL12855162 | 0.83 | SLC22A2 (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| 3-Hydroxyrimantadine SCHEMBL2739148 | 0.83 | SLC22A2 (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| 3-Hydroxyrimantadine SCHEMBL17818723 | 0.82 | MAPT (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL7454830 | 0.82 | DPP4 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| 3-Hydroxyrimantadine SCHEMBL17818722 | 0.82 | MAPT (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL14696758 | 0.80 | DPP4 (0.45) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | GRIN2D 4438/4885GRIN3B 3239/4885GRIN1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.